Patents by Inventor Bing Shi

Bing Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS
    Publication number: 20250136603
    Abstract: The present invention is related to processes for preparing antiviral prodrugs, co-crystals, solvents, salts or combinations thereof, and related synthetic intermediate compounds.
    Type: Application
    Filed: June 26, 2024
    Publication date: May 1, 2025
    Inventors: Andrei Chtchemelinine, Gregory Cizio, Christopher Discolo, John Enquist, Lucas Man, Sean T. Neville, Keshab Sarma, Bing Shi, Leon X. Sun, Kevin S. Williamson
  • SOLID FORMS
    Publication number: 20250101057
    Abstract: The present disclosure relates to crystalline and solvate forms of a nucleoside reverse transcriptase translocation inhibitor (NRTTI), and pharmaceutical compositions thereof, which are useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: June 26, 2024
    Publication date: March 27, 2025
    Inventor: Bing Shi
  • METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS
    Publication number: 20250100999
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Application
    Filed: September 10, 2024
    Publication date: March 27, 2025
    Inventors: Kevin McCormack Allan, Amanda Lynn Vandehey, Gediminas Brizgys, Sachin Dhar, Ian James Doxsee, Alex Goldberg, Lars V. Heumann, Zilin Huang, Nathaniel Thomas Kadunce, Shahrokh Kazerani, Willard Lew, Vinh Xuan Ngo, Brian Michael O'Keefe, Trevor James Rainey, Benjamin James Roberts, Bing Shi, Dietrich P. Steinhuebel, Winston C. Tse, Anna Michelle Wagner, Xianghong Wang, Scott Alan Wolckenhauer, Chloe Yuyi Wong, Jennifer R. Zhang
  • Crystalline forms of tenofovir alafenamide
    Patent number: 12202849
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: January 21, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • SOLID FORMS
    Publication number: 20250011352
    Abstract: The present disclosure relates to solid forms of compounds and pharmaceutical compositions thereof, which are useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus
    Type: Application
    Filed: May 30, 2024
    Publication date: January 9, 2025
    Inventors: Ekaterina V. Albert, Yisoo M. Hwang, Bing Shi
  • METHODS OF PREPARING 1'-CYANO NUCLEOSIDES
    Publication number: 20240409575
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Application
    Filed: May 6, 2024
    Publication date: December 12, 2024
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A.J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • CRYSTALLINE FORMS OF AN AZETIDINE PARP1 INHIBITOR
    Publication number: 20240317746
    Abstract: Described herein are crystalline forms of 5-(((2R,3S)-1-((7-chloro-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-2-methylazetidin-3-yl)oxy)-N-cyclopropylpicolinamide (Compound 1), or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: March 22, 2024
    Publication date: September 26, 2024
    Inventors: Jing Liu, Jayachandra P. Reddy, Bing Shi, Kathleen E. Navis
  • SOLID FORMS OF AN HIV CAPSID INHIBITOR
    Publication number: 20240254104
    Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-TH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: October 24, 2023
    Publication date: August 1, 2024
    Inventor: Bing Shi
  • Choline Salt Forms of an HIV Capsid Inhibitor
    Publication number: 20240245669
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3- (trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: October 24, 2023
    Publication date: July 25, 2024
    Inventors: Travis Lee Houston, Bing Shi
  • METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS
    Publication number: 20240101533
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Application
    Filed: June 5, 2023
    Publication date: March 28, 2024
    Inventors: Kevin McCormack Allan, Amanda Lynn Vandehey, Gediminas Brizgys, Sachin Dhar, Ian James Doxsee, Alex Goldberg, Lars V. Heumann, Zilin Huang, Nathaniel Thomas Kadunce, Shahrokh Kazerani, Willard Lew, Vinh Xuan Ngo, Brian Michael O`Keefe, Trevor James Rainey, Benjamin James Roberts, Bing Shi, Dietrich P. Steinhuebel, Winston C. Tse, Anna Michelle Wagner, Xianghong Wang, Scott Alan Wolckenhauer, Chloe Yuyi Wong, Jennifer R. Zhang
  • Solid forms of an HIV capsid inhibitor
    Patent number: 11845739
    Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yOpyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventor: Bing Shi
  • Choline salt forms of an HIV capsid inhibitor
    Patent number: 11833143
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 5, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Travis Lee Houston, Bing Shi
  • SOLID FORMS OF A COT INHIBITOR COMPOUND
    Publication number: 20230322727
    Abstract: Disclosed are solid forms of a Cot (cancer Osaka thyroid) inhibitor and corresponding methods of preparation thereof, wherein the Cot inhibitor has the following formula:
    Type: Application
    Filed: April 10, 2023
    Publication date: October 12, 2023
    Inventors: Kassibla E. Dempah, Bing Shi, Ana F. Voica, Kevin S. Williamson
  • METHODS OF PREPARING 1`-CYANO NUCLEOSIDES
    Publication number: 20230295214
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Application
    Filed: February 10, 2023
    Publication date: September 21, 2023
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A.J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • Solid forms of a Cot inhibitor compound
    Patent number: 11655237
    Abstract: Disclosed are solid forms of a Cot (cancer Osaka thyroid) inhibitor and corresponding methods of preparation thereof, wherein the Cot inhibitor has the following formula:
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 23, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Kassibla E. Dempah, Bing Shi
  • Methods of preparing 1?-cyano nucleosides
    Patent number: 11613553
    Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: March 28, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A. J. Uhlig, Tiago Vieira, Todd A. Wenderski
  • CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE
    Publication number: 20230091736
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 23, 2023
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • Crystalline forms of tenofovir alafenamide
    Patent number: 11440928
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 13, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • Choline Salt Forms of an HIV Capsid Inhibitor
    Publication number: 20220249460
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfony)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)- 3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: January 26, 2022
    Publication date: August 11, 2022
    Inventors: Travis Lee Houston, Bing Shi
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE49445
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 7, 2023
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin